OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

Candidates clashed but avoided talk of abortion at 4th GOP primary debate

Raised voices and sharp words marked Wednesday night’s fourth Republican presidential primary debate as four candidates argued about everything from their own electability to the

December 7, 2023

Pharmalittle: We’re reading about CAR-T drugs for myeloma, CVS rebate credits, and more

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and inspiring, because that oh-so familiar routine of online

March 18, 2024

Teen pregnancy may be associated with risk of premature mortality in early adulthood

The risk of early death beyond 12 years of age related to teenage pregnancies and gestational age.

March 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.